BACKGROUND: In Uganda, the main stay for provision of human immunodeficiency virus (HIV) voluntary counseling and testing (VCT) has been at health facilities. Home based VCT on the other hand, was initiated in the country to improve service coverage. OBJECTIVE: To evaluate the cost effectiveness of facility- and home-based HIV VCT strategies in rural southwestern Uganda. METHODS: Data on costs and effectiveness of facility- and home-based HIV VCT intervention strategies was collected in two sub-Counties in rural southwestern Uganda. Costing was performed using the ingredients approach. Effectiveness was measured as the number of HIV sero-positive clients identified. Incremental Cost-Effectiveness Ratios (ICERs) were calculated from the provider perspective. RESULTS: The cost per client tested were US$6.4 for facility based VCT and US$5.0 for home based VCT. The corresponding costs per positive case identified were US$86.5 and US$54.7 respectively. The incremental cost to providers per additional positive case identified by facility based VCT was US$3.5. CONCLUSION: Home based VCT was the least costly strategy per client tested and was also cost effective in identifying HIV sero-positive clients in rural areas. This strategy should therefore be promoted to improve service coverage and thereby facilitate early and extensive detection of clients eligible for treatment.
BACKGROUND: In Uganda, the main stay for provision of human immunodeficiency virus (HIV) voluntary counseling and testing (VCT) has been at health facilities. Home based VCT on the other hand, was initiated in the country to improve service coverage. OBJECTIVE: To evaluate the cost effectiveness of facility- and home-based HIV VCT strategies in rural southwestern Uganda. METHODS: Data on costs and effectiveness of facility- and home-based HIV VCT intervention strategies was collected in two sub-Counties in rural southwestern Uganda. Costing was performed using the ingredients approach. Effectiveness was measured as the number of HIV sero-positive clients identified. Incremental Cost-Effectiveness Ratios (ICERs) were calculated from the provider perspective. RESULTS: The cost per client tested were US$6.4 for facility based VCT and US$5.0 for home based VCT. The corresponding costs per positive case identified were US$86.5 and US$54.7 respectively. The incremental cost to providers per additional positive case identified by facility based VCT was US$3.5. CONCLUSION: Home based VCT was the least costly strategy per client tested and was also cost effective in identifying HIV sero-positive clients in rural areas. This strategy should therefore be promoted to improve service coverage and thereby facilitate early and extensive detection of clients eligible for treatment.
Entities:
Keywords:
Uganda; cost effectiveness; facility and home based VCT; positive cases identified
Authors: Nathan M Thielman; Helen Y Chu; Jan Ostermann; Dafrosa K Itemba; Anna Mgonja; Sabina Mtweve; John A Bartlett; John F Shao; John A Crump Journal: Am J Public Health Date: 2005-11-29 Impact factor: 9.308
Authors: Harry Peter Hausler; Edina Sinanovic; Lilani Kumaranayake; Pren Naidoo; Hennie Schoeman; Barbara Karpakis; Peter Godfrey-Faussett Journal: Bull World Health Organ Date: 2006-07 Impact factor: 9.408
Authors: Nick Menzies; Betty Abang; Rhoda Wanyenze; Fred Nuwaha; Balaam Mugisha; Alex Coutinho; Rebecca Bunnell; Jonathan Mermin; John M Blandford Journal: AIDS Date: 2009-01-28 Impact factor: 4.177
Authors: Joseph K B Matovu; Ronald H Gray; Noah Kiwanuka; Godfrey Kigozi; Fred Wabwire-Mangen; Fred Nalugoda; David Serwadda; Nelson K Sewankambo; Maria J Wawer Journal: AIDS Behav Date: 2006-10-03
Authors: M Sweat; S Gregorich; G Sangiwa; C Furlonge; D Balmer; C Kamenga; O Grinstead; T Coates Journal: Lancet Date: 2000-07-08 Impact factor: 79.321
Authors: Wei Chang; Gabriel Chamie; Daniel Mwai; Tamara D Clark; Harsha Thirumurthy; Edwin D Charlebois; Maya Petersen; Jane Kabami; Emmanuel Ssemmondo; Kevin Kadede; Dalsone Kwarisiima; Norton Sang; Elizabeth A Bukusi; Craig R Cohen; Moses Kamya; Diane V Havlir; James G Kahn Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: Laura M Bogart; Glenn J Wagner; William Musoke; Rose Naigino; Sebastian Linnemayr; Emily Maistrellis; David J Klein; Riana B Jumamil; Barbara Mukasa; Ingrid V Bassett; Thomas P Giordano; Rhoda K Wanyenze Journal: AIDS Behav Date: 2017-02
Authors: Laura M Bogart; Rose Naigino; Emily Maistrellis; Glenn J Wagner; William Musoke; Barbara Mukasa; Riana Jumamil; Rhoda K Wanyenze Journal: AIDS Behav Date: 2016-10